Review
Cardiovascular Disease in Pregnancy (Women’s Health Series)
Abstract
Cardiovascular disease is the leading cause of death generally and the most common cause of death during pregnancy in industrialized countries. Improvement in early diagnosis and treatment of congenital heart disease has increased the number of women with such conditions reaching reproductive age. The growing prevalence of diabetes, hypertension, obesity, hyperlipidemia, and metabolic syndrome has concurrently added to the population of pregnant women with acquired heart disease, including coronary artery disease. Physiologic changes occurring during pregnancy can stress a compromised cardiovascular system, resulting in maternal morbidity, mortality, and compromised fetal outcomes. These risks complicate affected women’s decisions to become pregnant, their ability to carry a pregnancy to term, and the complexity and risk benefit of cardiovascular treatments delivered during pregnancy. Risk assessment indices assist the obstetrician, cardiologist, and primary care provider in determining the general prognosis of the patient during pregnancy and although imperfect, can aid patients in making informed decisions. Treatments must be selected that ideally benefit the health of both mother and fetus and at a minimum limit risk to the fetus during gestation.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Trends in maternal mortality: 1990 to 2010. WHO, UNICEF, UNFPA, and the World Bank estimates.http://www.searo.who.int/maldives/documents/Trends_in_maternal_mortality_A4__1990–2010.pdf. Published 2012. Accessed May 2, 2013.
2. Ronsmans C, Graham WJ. Lancet Maternal Survival Series steering group. Maternal mortality: who, when, where, and why. Lancet. 2006; 368: 1189–2000.
3. Sachs BP, Brown DA, Driscoll SG, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med. 1987; 316: 667–672.
4. Hogan MC, Foreman KJ, Naghavi M, et al. Maternal mortality for 181 countries, 1980–2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet. 2010; 375: 1609–1623.
5. Gaskin IM. Maternal death in the United States: a problem solved or a problem ignored? J Perinat Educ. 2008; 17: 9–13.
6. Hill K, Thomas K, AbouZahr C, et al. Estimates of maternal mortality worldwide between 1990 and 2005: an assessment of available data. Lancet. 2007; 370: 1311–1319.
7. Hameed A. Cardiovascular disease and maternal mortality. http://www.acog.org/∼/media/Departments/Public%20Health%20and%20Social%20Issues/20120506-13.pdf?dmc=1&ts=20130923T1436530188. Published May 2012. Accessed September 23, 2013.
7a. Gissler M, Deneux-Tharaux C, Alexander S, et al. Pregnancy-related deaths in four regions of Europe and the United States in 1999–2000: characterisation of unreported deaths. Eur J Obstet Gynecol Reprod Biol. 2007; 133: 179–185.
8. Atrash HK, Rowley D, Hogue CJ. Maternal and perinatal mortality. Curr Opin Obstet Gynecol. 1992; : 4: 61–71.
9. Pregnancy mortality surveillance system. Trends in pregnancy-related mortality in the United States, 1987–2008. http://www.cdc.gov/reproductivehealth/MaternalInfantHealth/PMSS.html. Accessed May 2, 2013.
10. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013; 127: e6–e245.
11. Otto H, Saether SG, Banteyrga L, et al. High prevalence of subclinical rheumatic heart disease in pregnant women in a developing country: an echocardiographic study. Echocardiography. 2011; 28: 1049–1053.
12. Gentry MB, Dias JK, Luis A, et al. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010; 55: 654–659.
13. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009; 113: 1299–1306.
14. Berg CJ, Callaghan WM, Syverson C, et al. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol. 2010; 116: 1302–1309.
15. Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007; 115: 163–172.
16. Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010; 31: 2124–2132.
17. Stangl V, Schad J, Gossing G, et al. Maternal heart disease and pregnancy outcome: a single centre experience. Eur J Heart Fail. 2008; 10: 855–860.
18. Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol. 2007; 49: 2303–2311.
19. Lui GK, Silversides CK, Khairy P, et al. Heart rate response during exercise and pregnancy outcome in women with congenital heart disease. Circulation. 2011; 123: 242–248.
20. Sui SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104: 515–521.
21. Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation. 2006; 113: 517–524.
22. Ladner HE, Danielsen B, Gilbert WM . Acute myocardial infarction in pregnancy and the puerperium: a population-based study. Obstet Gynecol. 2005; 105: 480–484.
23. Regitz-Zagrosek V, Blomstrom-Lundqvist CB, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 3147–3197.
24. Easterling TR, Benedetti TJ, Schmucker BC, et al. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol. 1990; 76: 1061–1069.
25. McAnulty JH. Heart disease and pregnancy. In: Fuster V, Walsh RA, Harrington RA. , eds. Hurst’s The Heart. New York: McGraw-Hill; 2011; : 2147–2148.
26. Campos O. Doppler echocardiography during pregnancy: physiologic and abnormal findings. Echocardiography. 1996; 13: 135–146.
27. Edouard DA, Pannier BM, London GM, et al. Venous and arterial behavior during normal pregnancy. Am J Physiol. 1998; : 274: h1605–h1612.
28. Kafka H, Johnson MR, Gatzoulis MA. The team approach to pregnancy and congenital heart disease. Cardiol Clin. 2006; 24: 587–605.
29. Sullivan JM, Ramanathan KB. Management of medical problems in pregnancy—severe cardiac disease. N Engl J Med. 1985; 313: 304–309.
30. Abbas AE, Lester SJ, Connolly H. Pregnancy and the cardiovascular system. Int J Cardiol. 2005; 98: 179–189.
31. Donnelly RT, Pinto NM, Kocolas I, et al. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. J Am Coll Cardiol. 2012; 60: 224–229.
32. Uebing A, Steer PJ, Yentis SM, et al. Pregnancy and congenital heart disease. BMJ. 2006; : 332: 401–406.
33. Thorne S, MacGregor A, Nelson-Piercy C. Risk of contraception and pregnancy in heart disease. Heart. 2006; 92: 1520–1525.
34. Yap SC, Drenthen W, Pieper PG, et al. Risk of complications during pregnancy in women with congenital aortic stenosis. Int J Cardiol. 2008; 126: 240–246.
35. James AH, Jamison MG, Biswas MS, et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation. 2006; 113: 1564–1571.
36. Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol. 2008; 52: 171–180.
37. Leonhardt G, Gaul C, Nietsh HH, et al. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006; 21: 271–276.
38. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guideline. J Am Coll Cardiol. 2013; 61: e78–e140.
39. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006; 97: 1765–1768.
40. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001; 344: 1567–1571.
41. Habli M, O’Brien T, Nowack E, et al. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol. 2008; 199: 415e1–415-e5
42. Elkayam U, Jalnapurkar S, Barakat M. Peripartum cardiomyopathy. Cardiol Clin. 2012; 30: 435–440.
43. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009; 15: 645–650.
44. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991–1997. Obstet Gynecol. 2003; 102: 1326–1331.
45. Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40: 1864–1869.
46. Avila WS, Amaral FM, Ramires JA, et al. Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy. Arq Bras Cardiol. 2007; 88: 423–428.
47. Mahli A, Izdes S, Coskun D. Cardiac operations during pregnancy: review of factors influencing fetal outcome. Ann Thorac Surg. 2000; 69: 1622–1626.
48. Frishman WH, Elkayam U, Aronow WS. Cardiovascular drugs in pregnancy. Cardiol Clin. 2012; 30: 463–491.
49. Pieper PG. Pre-pregnancy risk assessment and counselling of the cardiac patient. Neth Heart J. 2011; 19: 477–481.
